Stefania Bellone Selected Research

DHES0815A

11/2021

DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stefania Bellone Research Topics

Disease

88	Neoplasms (Cancer) 01/2022 - 05/2002
52	Carcinoma (Carcinomatosis) 01/2022 - 11/2003
25	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 05/2002
24	Endometrial Neoplasms (Endometrial Cancer) 01/2022 - 08/2004
24	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2020 - 12/2002
14	Papillary Carcinoma 01/2019 - 10/2004
10	Carcinosarcoma 01/2022 - 06/2007
7	Ovarian Epithelial Carcinoma 10/2017 - 02/2007
5	Ovarian Diseases (Ovarian Disease) 12/2015 - 07/2009
5	Endometrioid Carcinoma 12/2011 - 05/2005
4	Disease Progression 10/2021 - 08/2008
4	Adenocarcinoma 01/2020 - 09/2008
4	Neoplasm Metastasis (Metastasis) 11/2016 - 11/2003
4	Ascites 01/2016 - 06/2004
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 11/2019 - 06/2011
2	Uterine Neoplasms (Uterine Cancer) 01/2018 - 06/2004
2	Bites and Stings (Sting) 01/2016 - 02/2015
2	Infections 01/2012 - 07/2009

Drug/Important Bio-Agent (IBA)

23	Proteins (Proteins, Gene)FDA Link 10/2018 - 01/2005
12	Trastuzumab (Herceptin)FDA Link 11/2021 - 05/2002
11	Immunoconjugates (Immunoconjugate)IBA 11/2021 - 10/2014
10	ParaffinIBA 01/2020 - 11/2003
9	Paclitaxel (Taxol)FDA LinkGeneric 10/2021 - 08/2004
9	Claudin-3IBA 01/2019 - 10/2004
9	Monoclonal AntibodiesIBA 10/2018 - 07/2009
8	Epithelial Cell Adhesion MoleculeIBA 01/2016 - 10/2004
8	Messenger RNA (mRNA)IBA 01/2016 - 06/2007
7	Claudin-4IBA 01/2019 - 10/2004
7	Clostridium enterotoxinIBA 01/2017 - 05/2005
7	AntigensIBA 07/2009 - 06/2003
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 05/2005
6	PlatinumIBA 01/2022 - 08/2010
6	sacituzumab govitecanIBA 02/2020 - 08/2018
6	Interleukin-2 (IL2)IBA 12/2011 - 08/2003
5	neratinibIBA 01/2022 - 10/2014
5	Pharmaceutical PreparationsIBA 10/2021 - 10/2010
5	Carboplatin (JM8)FDA LinkGeneric 10/2021 - 08/2004
5	Formaldehyde (Formol)FDA Link 01/2020 - 10/2004
5	Epidermal Growth Factor (EGF)IBA 11/2016 - 08/2004
5	CytokinesIBA 01/2016 - 06/2003
5	Peptides (Polypeptides)IBA 12/2015 - 06/2006
5	epothilone B (EPO906)IBA 01/2014 - 10/2010
5	Oncogene Proteins (Oncogene Protein)IBA 07/2009 - 05/2003
5	EnzymesIBA 02/2009 - 01/2004
5	Serine Proteases (Serine Protease)IBA 02/2009 - 11/2003
4	EpitopesIBA 11/2021 - 06/2006
4	Membrane Glycoproteins (Membrane Glycoprotein)IBA 01/2020 - 12/2010
4	TubulinIBA 01/2014 - 04/2012
4	VaccinesIBA 07/2009 - 01/2005
4	Kallikreins (Kallikrein)IBA 05/2006 - 08/2004
4	Peptide Hydrolases (Proteases)FDA Link 10/2004 - 11/2003
3	olaparibIBA 01/2022 - 10/2019
3	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2018
3	taxaneIBA 01/2022 - 07/2013
3	copanlisibIBA 08/2020 - 11/2019
3	Irinotecan (Camptosar)FDA LinkGeneric 01/2020 - 01/2020
3	Surface Antigens (Surface Antigen)IBA 01/2020 - 01/2020
3	DNA (Deoxyribonucleic Acid)IBA 11/2019 - 02/2013
3	DuocarmycinsIBA 10/2017 - 01/2016
3	Ado-Trastuzumab EmtansineIBA 10/2017 - 01/2017
3	trastuzumab duocarmazineIBA 10/2017 - 01/2016
3	DNA-Directed DNA Polymerase (Polymerases, DNA)IBA 01/2017 - 04/2015
3	SolitomabIBA 01/2016 - 02/2015
3	ChromiumIBA 01/2016 - 06/2006
3	Complement System Proteins (Complement)IBA 05/2012 - 09/2007
3	adecatumumabIBA 12/2010 - 01/2010
2	Adenosine Diphosphate Ribose (ADP-Ribose)IBA 01/2022 - 10/2019
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2022 - 10/2019
2	Adenosine Diphosphate (ADP)IBA 01/2022 - 10/2019
2	ixabepilone (BMS 247550)FDA Link 01/2022 - 07/2013
2	pembrolizumabIBA 01/2022 - 01/2018
2	pertuzumabIBA 11/2021 - 10/2017
2	NivolumabIBA 01/2020 - 12/2016
2	AfatinibIBA 11/2019 - 01/2019
2	Interleukin-6 (Interleukin 6)IBA 01/2018 - 07/2005
2	Exonucleases (3' 5' Exonuclease)IBA 12/2016 - 07/2015
2	IntegrinsIBA 11/2016 - 08/2011
2	HLA-DR Antigens (HLA-DR)IBA 01/2016 - 10/2015
2	Fluorescein-5-isothiocyanate (FITC)IBA 12/2015 - 07/2010
2	5-(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE)IBA 10/2015 - 07/2015
2	Mechanistic Target of Rapamycin Complex 1IBA 12/2013 - 11/2013
2	Epothilones (Epothilone)IBA 07/2013 - 07/2013
2	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 07/2013 - 07/2013
2	Small Interfering RNA (siRNA)IBA 12/2011 - 10/2011
2	Tight Junction ProteinsIBA 12/2011 - 05/2005
2	Thromboplastin (Tissue Factor)IBA 10/2011 - 06/2011
2	A-factor (Streptomyces)IBA 10/2011 - 06/2011
2	hI-con1IBA 10/2011 - 06/2011
2	Rituximab (Mabthera)FDA Link 07/2011 - 06/2011
2	RNA (Ribonucleic Acid)IBA 07/2009 - 07/2009
2	Interferon-gamma (Interferon, gamma)IBA 02/2009 - 01/2009
2	ImmunosorbentsIBA 02/2009 - 07/2005

Therapy/Procedure

48	Drug Therapy (Chemotherapy) 01/2022 - 05/2002
30	Therapeutics 01/2021 - 05/2002
19	Immunotherapy 05/2012 - 05/2003
7	Radiotherapy 01/2021 - 12/2002
4	Intravenous Administration 10/2021 - 01/2020
4	Salvage Therapy 01/2018 - 06/2003
2	Injections 10/2021 - 04/2007
2	Intraperitoneal Injections 01/2017 - 04/2007